Copyright Reuters
Oct 30 (Reuters) - Biotech firm CSL (CSL.AX), opens new tab said on Thursday its vaccine arm, CSL Seqirus and Vaccine Industrial Company, had inked a deal with Saudi Arabia's Health Ministry to localize manufacturing of cell-based seasonal and pandemic influenza vaccines. The deal comes a few days later after Australia's CSL said it was no longer targeting to complete the spin off of Seqirus in fiscal 2026 amid heightened volatility in the U.S. vaccine markets. Sign up here. Reporting by Nichiket Sunil in Bengaluru; Editing by Rashmi Aich
